QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Boulis, A. Articles by Ubel, P. A. Search for Related Content PubMed PubMed Citation

Responding to the Immunoglobulin Shortage: A Case Study

Susan Goold and Peter A. Ubel
University of Michigan

Abstract.

In fall 1997, a shortage of intravenous immunoglobulin (IVIG) developed in the United States because of increased demand for the product, reduced supply, and product recalls. This shortage is a useful model for understanding how our health care system responds to scarcity. Although the U.S. government took steps to inform the medical community of the shortage, with few exceptions, the government did not respond to the shortage in a timely or effective manner. Instead, it took a relatively passive role, leaving IVIG manufacturers and distributors, health care institutions, and clinicians to fend for themselves. The shortage likely had an uneven impact on patients, based on the relative market strength of the health care institutions in which they received care and the individual patient's ability to absorb the increasing out-of-pocket costs of scarce IVIG. Market mechanisms have now largely alleviated the shortage and significantly reduced its detrimental impact on patients. However, future shortages of IVIG or other scarce medical products, such as vaccines and antibiotics, would benefit from more immediate and coordinated efforts not only to make sure that scarce health care resources are distributed in a just manner but also to identify and remedy the sources of health product supply problems.

This article has been cited by other articles:

				D. Provan, H. M Chapel, W A C. Sewell, D. O'Shaughnessy, and on behalf of the UK Immunoglobulin Expert Working Prescribing intravenous immunoglobulin: summary of Department of Health guidelines BMJ, October 20, 2008; 337(oct20_2): a1831 - a1831. [Full Text]

				J. M. Hoffman, N. D. Shah, L. C. Vermeulen, G. T. Schumock, P. Grim, R. J. Hunkler, and K. M. Hontz Projecting future drug expenditures--2006 Am. J. Health Syst. Pharm., January 15, 2006; 63(2): 123 - 138. [Abstract] [Full Text] [PDF]

				G. C. Alexander, R. M. Werner, and P. A. Ubel The Costs of Denying Scarcity Arch Intern Med, March 22, 2004; 164(6): 593 - 596. [Full Text] [PDF]